Oral Carbon Monoxide Enhances Autophagy Modulation in Prostate, Pancreatic, and Lung Cancers

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Autophagy inhibition shows promise for cancer treatment, but clinical efficacy is inconsistent.
• Hydroxychloroquine is an autophagy inhibitor used in cancer therapy.
• Smoking is linked to altered autophagy inhibition by hydroxychloroquine.

Purpose of the Study:

• To identify clinical and epidemiological factors associated with autophagy inhibition and positive cancer treatment response.
• To investigate the role of carbon monoxide (CO) in enhancing autophagy inhibition for cancer therapy.

Main Methods:

• Retrospective analysis of patients treated with hydroxychloroquine.
• Investigated correlation between smoking status and hydroxychloroquine's autophagy inhibition.
• Pre-clinical models using a novel CO-releasing material to test combination therapy.

Main Results:

• A direct correlation was found between smoking status and hydroxychloroquine-induced autophagy inhibition.
• Supplemental carbon monoxide (CO) significantly enhanced the cytotoxicity of autophagy inhibitors.
• Combination therapy with CO and autophagy inhibitors markedly inhibited tumor growth in pre-clinical models.

Conclusions:

• Therapeutic levels of carbon monoxide can significantly enhance the efficacy of autophagy inhibitors in cancer treatment.
• This finding opens a new therapeutic avenue for improving cancer therapies by combining CO with autophagy inhibition.